

[For Immediate Release]



The United Laboratories International Holdings Limited

Obtained Drug Registration Approval from
The State Food and Drug Administration

(28 September 2008 – Hong Kong) – The United Laboratories International Holdings Limited (“TUL” or the “Group”; Stock code: 3933), one of the leading manufacturers of antibiotics in the PRC, announced that the self-developed Imipenem Cilastatin Sodium for injection has recently obtained Drug Registration Approval from the State Food and Drug Administration.

Imipenem Cilastatin Sodium for injection provides treatment for various types of infections, especially for moderate and severe ones. This product has a wide antibacterial spectrum and shows apparent clinical therapeutic effect, which makes it one of the best antibiotics. According to Shanghai Institute of Pharmaceutical Industry, Imipenem Cilastatin Sodium for injection is the Top 50 medicines used in hospital, with an annual growth rate of 31.5%, accounting for 31.16% of Carbapenem. The data from Chinese Pharmaceutical Association regarding medicine used in major cities’ hospitals shows that the consumption amount of Imipenem Cilastatin Sodium for injection increased steadily every year since it first launch in 2000. Nowadays, the Imipenem Cilastatin Sodium for injection is mainly imported, but new products of TUL will replace some of the imported products in future and at the same time strengthen the Group’s leading position in the antibiotics industry.

Mr. Choy Kam Lok, Chairman of TUL, said “As the registration procedure for new drugs is tightening, we are pleased to obtain another registration approval for our self-developed medicine from the State Food and Drug Administration. This does not only demonstrate the administration’s recognition of our product quality, but also strengthen our confidence in research and development. At present, 25 finished products are under development by the Group, focusing mainly on antibiotics, medicines for diabetes, cardiovascular, hepatitis B and nutrition products, some of them are patent products. During the year, we will continue the research and development for more than five new finished products, including the research and development of two insulin analogues, which will complement our insulin products and optimize the Group’s product structure. We will continue to develop quality medicines with high effectiveness and competitive price, and strive to safeguard healthcare benefits of the Chinese.”

- End -

Company Background

Listed on the Stock Exchange of Hong Kong in June 2007, **TUL** is one of the major manufacturers of antibiotic products in China and principally engaged in the manufacturing and selling of bulk medicine and intermediate products used to produce antibiotics, and also antibiotics as finished goods. The Group also produces and sells, in smaller amounts, cough syrup, anti-allergy medicine as well as empty capsule casings. As of 30 June 2008, the Group has a total of 156 products qualified to produce in the PRC and/Hong Kong based on the Drug Registration Approvals in the PRC and Certificates of Drug or Product Registration in Hong Kong, including 36 bulk medicines and 120 finished products.

For further enquiries, please contact
iPR Ogilvy Ltd.

Sandy Yeung/ Stephanie Yuen / Tina Law / Callis Lau
Tel: (852) 2136 8072/ 3170 6609/ 2136 6181/ 2136 6952
Fax: (852) 3170 6606
E-mail: sandy.yeung@iprogilvy.com/ stephanie.yuen@iprogilvy.com/
tina.law@iprogilvy.com/ callis.lau@iprogilvy.com